MannKind's Afrezza met the primary endpoint in a Phase 3 trial, demonstrating non-inferiority to multiple daily insulin injections (MDI) in pediatric patients aged 4-17.
Eli Lilly's efsitora alfa, a once-weekly insulin, demonstrated non-inferior A1C reduction compared to daily insulin glargine in insulin-naïve adults with type 2 diabetes.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.